Rentschler Taps Veteran CEO to Steer Renewed Focus on Biologics

LAUPHEIM, Germany, and MILFORD, MA, USA – July 01, 2026 – Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO), today announced a significant leadership transition, appointing Dr. Torsten Woehr as its new Chief Executive Officer, effective August 1, 2026. This move signals more than a simple change at the top; it represents the crucial execution phase of a refined corporate strategy designed to double down on the company's core strengths in a rapidly evolving biopharmaceutical landscape.

Dr. Woehr, a seasoned executive with over 25 years of experience in the international CDMO and biotechnology sectors, joins the family-owned company at a pivotal moment. His appointment follows a period of strategic realignment and substantial investment, positioning him to guide Rentschler Biopharma's next chapter of growth and value creation. He will take the helm from Prof. Dr. Uwe Buecheler, who provided outstanding interim leadership and will now return to his role as Vice Chairman of the Supervisory Board.

A Strategic Pivot to Core Strengths

To fully appreciate the significance of Dr. Woehr's appointment, one must look back to early 2025. At that time, Rentschler Biopharma made the decisive, and likely difficult, choice to withdraw from the cell and gene therapy (CGT) space, ceasing operations at its UK site in Stevenage. While the CGT market holds immense promise, the company's strategic review concluded that its growth was not materializing at the expected pace. Instead of spreading its resources thin, Rentschler opted for strategic discipline, choosing to intensify its focus on its well-established and thriving biologics business.

This pivot makes the selection of Dr. Woehr particularly astute. His mandate is not to explore nascent fields but to scale and optimize a proven engine of growth. The challenges in the biologics market—from monoclonal antibodies to complex proteins—are not in proving their efficacy, but in navigating the immense complexity of their development and manufacturing. This is where Dr. Woehr's deep operational understanding and commercial leadership, honed most recently as Chief Commercial Officer at Bachem Group, become critical assets. His track record is not just in growth, but in sustainable growth, aligning commercial goals with operational realities to build lasting partnerships.

Prof. Dr. Nikolaus F. Rentschler, Chairman of the Supervisory Board, emphasized this alignment in his statement: “At a time when our clients are navigating increasing complexity in biologics development and manufacturing, his expertise in aligning commercial priorities with operational capabilities and strengthening partnerships will be critical.”

The Transatlantic Leader for a Global Ambition

Dr. Woehr's profile is uniquely suited to Rentschler Biopharma’s global footprint, which is firmly anchored on both sides of the Atlantic. His more than a decade of professional experience in the United States is not a minor detail; it is a core competency that aligns directly with the company's largest-ever strategic investments.

Since acquiring its site in Milford, Massachusetts, in 2019, Rentschler has transformed it into a cornerstone of its global strategy. In 2024, a new production line became fully operational, an expansion that effectively doubled the company's global cGMP manufacturing capacity. This state-of-the-art facility, equipped with four 2,000 L single-use bioreactors, is now onboarding a diverse portfolio of client projects. Dr. Woehr's transatlantic experience provides the cultural and business fluency needed to maximize this critical U.S. asset, ensuring seamless integration with the company's German headquarters in Laupheim, which is itself undergoing a major upgrade with a new buffer media station set to be operational by 2028.

His role will be to leverage these dual hubs of excellence to serve a global clientele, fostering the kind of deep, impactful client engagement that turns a service provider into an indispensable partner. This is the essence of creating lasting value in the CDMO sector—moving beyond transactional manufacturing to become an integral part of a client’s journey from lab to patient.

Navigating a Dynamic CDMO Landscape

The biologics market is a paradox of opportunity and pressure. On one hand, demand is surging, fueled by breakthroughs in therapies for cancer, autoimmune diseases, and metabolic disorders. This has led to a boom in outsourcing as pharmaceutical companies seek specialized expertise to de-risk their pipelines and accelerate time-to-market. On the other hand, the industry faces significant headwinds, including persistent supply chain fragility, intense competition, and a shifting geopolitical landscape that is causing many to re-evaluate their global manufacturing strategies.

In this environment, success for a CDMO like Rentschler Biopharma depends on more than just capacity. It requires operational excellence, technological innovation, and a proactive approach to partnership. Dr. Woehr’s appointment is a clear acknowledgment of these market realities. His experience in scaling operations and driving business performance will be essential for ensuring that Rentschler's expanded capacity is utilized efficiently and effectively. His focus on strengthening strategic partnerships directly addresses the market's demand for reliable, long-term manufacturing solutions.

Enhancing Value Through Partnership and Innovation

In his own words, Dr. Woehr expressed his excitement to “build on this solid foundation to further enhance our capabilities and create lasting impact for our partners, our clients and patients worldwide.” This statement reflects a modern understanding of the CDMO business model, where value is co-created with clients.

This philosophy is already evident in Rentschler Biopharma’s strategy. The company’s 2025 strategic collaboration with Coriolis Pharma, a specialist in formulation research, is a prime example. By integrating early-stage formulation development with late-stage manufacturing, the partnership offers clients a seamless, end-to-end solution that can significantly accelerate development timelines. This, combined with its long-standing 'Xpert Alliance' with Vetter for aseptic filling, creates a powerful ecosystem of expertise.

Dr. Woehr's leadership will be instrumental in deepening these collaborations and identifying new synergies that improve the client experience. His mission is clear: to lead a talented and dedicated team in advancing medicine, guided by the vision of saving lives. As Rentschler Biopharma embarks on this next phase, it does so with a leader whose experience is perfectly matched to the strategic demands of the moment.